Skip to main content
. 2022 Oct 30;10:36–38. doi: 10.1016/j.jdin.2022.10.006

Table I.

Prevalence rates of injection site reactions

Biologics (N = 141) Prevalence rate of ISRs, n (%)
Ixekizumab (n = 20) 11 (55.0)
Guselkumab (n = 42) 6 (14.3)
Adalimumab (n = 11) 1 (9.1)
Risankizumab (n = 14) 1 (7.1)
Ustekinumab (n = 22) 0
Secukinumab (n = 32) 0

ISRs, Injection site reactions.